Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Catalyst Biosciences Expected to Initiate Clinical Efficacy Trial in Hemophilia A and B Inhibitor Patients

Source Link:: http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-newsArticle&ID=2193026

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CBIO

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Catalyst Biosciences expects to begin a clinical efficacy study of CB 813d/PF-05280602, a long-acting coagulation Factor VIIa, in the later part of 2016. The Company's development of CB 813d recently finished a phase 1 study in June 2015 and intend to have a new study initiated by the end of 2016.

http://ir.catalystbi...

Additional Relevant Details CB 813d, the Company’s next-generation high potency Factor VIIa for Hemophilia A and B inhibitor patients is expected to enter a subcutaneous prophylaxis trial in 2017.

http://ir.catalystbi...

Additional Relevant Details August 4th, 2016 - Note: This trial was initially expected to occur in 2016, but has been delayed. Original source below.

http://ir.catalystbi...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 14, 2017

Occurred Source:

http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-newsArticle&ID=2280849

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Hemophilia B, Hemophilia A, Clinical Study, Factor Viia